We go beyond medication to approach the different pathologies in a holistic way, with the focus always on the patient
Business
DISEASES
We want to approach the treatment of specific disabling pathologies life with a holistic view that involves centering on the disease at the centre to reduce its negative social effects and make living with the disease more bearable.
-
Huntington's disease
It is a rare, hereditary neurodegenerative disease that causes progressive neuronal death, manifesting as a decline in cognitive, behavioral, and motor functions. -
Amyotrophic lateral sclerosis
A neurodegenerative pathology that causes muscle weakness. -
Progressive supranuclear palsy
A brain disorder that affects balance, vision, and movement. -
Pulmonary hypertension
A disease caused by high blood pressure in the blood vessels of the lungs. -
Pulmonary arterial hypertension
A specific type of pulmonary hypertension that directly affects the pulmonary arteries. -
Pulmonary hypertension associated with interstitial lung disease
High blood pressure in the pulmonary vessels associated with interstitial lung diseases. -
Idiopathic pulmonary fibrosis
Progressive lung scarring with no known cause. -
Progressive pulmonary fibrosis
A lung disease characterized by a progressive decline in respiratory function.
Understanding to transform
We look beyond the drug because we know that behind every diagnosis there is a person, and that the experience of the disease is not defined only by its clinical aspects, but by a broader environment of relationships, systems and interactions. For this reason, we take a comprehensive view that leads us to understand the ecosystem that surrounds each disease, working together with patients, caregivers, healthcare professionals, researchers, regulators and associations.
This knowledge allows us to move towards more relevant solutions with a greater real impact, which transcend the treatment itself and address aspects such as awareness, diagnosis, access or accompaniment. We understand that the impact of the disease goes beyond the person, also affecting those around them, and that progress is only possible through collaboration. Therefore, we promote dialogue and shared learning to help generate lasting value for all those affected.
Related news
-
Ferrer and Prilenia Announce Start of PRECISE-HD Confirmatory Clinical Trial of Pridopidine in Huntington's Disease
5 -
First participant in Europe in the Phase 3 clinical trial "PREVAiLS" with pridopidine, in ALS
5 -
IMPAHCT celebrates its eighth edition by reinforcing the comprehensive approach to rare lung diseases
5 -
Ferrer Spain promotes the foundations of a new value-based public procurement model
5 -
We completed the recruitment of 220 patients for PROSPER, the Phase II clinical trial in progressive supranuclear palsy
5
